Omega aminoalkylamides of R-2 aryl propionic acids as inhibitors of the chemotaxis of polymorphonucleate and mononucleate cells
(R)-2-Arylpropionamide compounds of formula (I) are described. The process for their preparation and pharmaceutical preparations thereof are also described. The 2-Arylpropionamides of the invention are useful in the prevention and treatment of tissue damage due to the exacerbate recruitment of polymorphonuclear leukocytes (leukocytes PMN) and of monocytes at the inflammatory sites. In particular, the invention relates to the R enantiomers of omega-aminoalkylamides of 2-aryl propionic acids, of formula (I), for use in the inhibition of the chemotaxis of neutrophils and monocytes induced by the C5a fraction of the complement and by other chemotactic proteins whose biological activity is associated with activation of a 7-TD receptor. Selected compounds of formula (I) are dual inhibitors of both the C5a-induced chemotaxis of neutrophils and monocytes and the IL-8-induced chemotaxis of PMN leukocytes. The compounds of the invention are used in the treatment of psoriasis, ulcerative cholitis, glomerular nephritis, acute respiratory insufficiency, idiopathic fibrosis, rheumatoid arthritis and in the prevention and the treatment of injury caused by ischemia and reperfusion.
1. A pharmaceutical composition consisting of (R)-2-Aryl-propionamide compound of formula (I)
or a pharmaceutically acceptable salt thereof,
wherein
Ar is a group selected from 4-isobutylphenyl, 2-(2,6-dichloro-phenyl-amino)-phenyl, or a phenyl 3-substituted with a group selected from the group consisting of benzoyl, isopropyl, isobutyl, pent-3-yl, 1-phenylethylen-1-yl, α-methylbenzyl, α-hydroxybenzyl, and α-hydroxyethyl,
R represents hydrogen,
X is a linear or branched C1-C6 alkylene,
R1 and R2 are:
independently hydrogen or methyl; or
R1 and R2 together with the N atom to which they are bound, form a 6 membered ring of formula (II) selected from the group consisting of 1-piperidinyl and morpholinyl
wherein the compound of the formula (I) has activity of inhibition of C5a-induced chemotaxis of polymorphonucleate leukocytes and monocytes and is devoid of any significant activity of inhibition of a cyclooxygenase enzyme.
2. The composition according to claim 1 , in which the compound of the formula I has activity as an inhibitor of IL-8 induced chemotaxis of polymorphonucleate leukocytes.
3. The composition of claim 1 , wherein X is a C2-C4 alkylene.
4. The composition according to claim 1 wherein said compound of formula (I) is selected from the group consisting of:
(R)-2-[(4-isobutyl)phenyl]-N-(2-dimethylaminoethyl)propionamide;
(R)-2-[(4-isobutyl)phenyl]-N-(3-dimethylaminopropyl)propionamide;
(R)-2-[(4-isobutyl)phenyl]-N-(3-aminopropyl)propionamide;
(R)-2-[(4-isobutyl)phenyl]-N-(4-dimethylaminobutyl)-propionamide;
(R)-2-[(4-isobutyl)phenyl]-N-3-(N-morpholinylpropyl)propionamide;
(R)-2-[(4-isobutyl)phenyl]-N-3-(1-piperidinylpropyl)propionamide;
(R)-2-[(3-isopropyl)phenyl]-N-(3-dimethylaminopropyl)propionamide;
(R)-2-(3-benzoylphenyl)-N-3-(dimethylaminopropyl)propionamide;
2-[2-(2,6-dichlorophenylamino)-phenyl]-N-3-(dimethylaminopropyl)propionamide.
5. The composition according to claim 1 wherein said compound of formula (I) is selected from the group consisting of:
(R)-2-(4-isobutylphenyl)-N-(3-dimethylamino-propyl)propionamide hydrochloride,
(R)-2-(4-isobutylphenyl)-N-3-(1-piperidinylpropyl)propionamide hydrochloride, and
(R)-2-(3-benzoylphenyl)-N-3-(dimethylamino-propyl) propionamide.